- Title
- The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
- Creator
- Attia, John R.; Holliday, Elizabeth; Ranasinghe, Priyanga; Jayawardena, Ranil; Samman, Samir; Luu, Judy; Rissel, Chris; Acharya, Shamasunder; Weaver, Natasha; Peel, Roseanne; Fleming, Kerry C.; Hure, Alexis; Wiggers, John; McEvoy, Mark; Searles, Andrew; Reeves, Penny
- Relation
- Acta Diabetologica Vol. 59, Issue 7, p. 965-975
- Publisher Link
- http://dx.doi.org/10.1007/s00592-022-01888-x
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2022
- Description
- Aims: The burden and health costs of Type 2 Diabetes Mellitus continue to increase globally and prevention strategies in at-risk people need to be explored. Previous work, in both animal models and humans, supports the role of zinc in improving glucose homeostasis. We, therefore, aimed to test the effectiveness of zinc supplementation on glycaemic control in pre-diabetic adults. Methods: We conducted a randomized, double-blind, placebo-controlled trial across 10 General Practitioner (GP) practices in NSW, Australia. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD)Study. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7–6.4%, 39–46 mmol/mol) men and women (N = 98) were all assigned to a free state government telephone health coaching service (New South Wales Get Healthy Information and Coaching Service) and then randomised to either daily 30 mg zinc gluconate or placebo. Blood tests were collected at baseline, 1, 6 and 12 months for the primary outcomes (HbA1c, fasting blood glucose (FBG)); secondary outcomes included Homeostasis Model Assessment 2 (HOMA 2) parameters, lipids, body weight, height, waist circumference, blood pressure and pulse. Results: The baseline-adjusted mean group difference at 6 months, expressed as treatment–placebo, (95% CI) was −0.02 (−0.14, 0.11, p = 0.78) for HbA1c and 0.17 (−0.07, 0.42; p = 0.17) for FBG, neither of which were statistically significant. There were also no significant differences between groups in any of the secondary outcomes. Zinc was well tolerated, and compliance was high (88%). Conclusion: We believe our results are consistent with other Western clinical trial studies and do not support the use of supplemental zinc in populations with a Western diet. There may still be a role for supplemental zinc in the developing world where diets may be zinc deficient.
- Subject
- prediabetes; zinc supplementation; randomized controlled trial; prevention; diabetes prevention; general practice; SDG 3; SDG 17; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1464403
- Identifier
- uon:46986
- Identifier
- ISSN:0940-5429
- Rights
- This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
- Language
- eng
- Full Text
- Reviewed
- Hits: 3533
- Visitors: 3676
- Downloads: 165
Collections
Goal 17: Partnerships for the Goals
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 762 KB | Adobe Acrobat PDF | View Details Download |